Responsiveness of the MOS-HIV and EQ-5D in HIV-infected adults receiving antiretroviral therapies

Table 1 Summary of MOS-HIV effect sizes overall and in treatment naïve and treatment-experienced HIV-infected patients

Study	Treatment	Physical health summary			Mental health summary
Study	Treatment	Mean change	% change	Effect size	Mean change	% change	Effect size
Bucciardini et al. 2007 [13]	ddI/d4T/EFV	4.7	9.4%	−0.43	4.0	8.2%	−0.40
	ddI/d4T/NFV	0.7	1.5%	−0.05	2.8	5.8%	−0.28
	ddI/d4T/EFV/NFV	2.0	4.2%	−0.17	0.0	0.0%	0.00
Stangl et al. 2007^a [23]	HAART + weekly home visits	15.0*	38.3%	−1.53	14.2*	35.5%	−1.27
Average for treatment-naïve patients [weighted]		2.5	0.1	−0.55	2.3	0.1	−0.49
Nuesch et al. 2009^b [17]	Continuous treatment	−1.3	−2.4%	0.20	0.8	1.5%	0.03
Nuesch et al. 2009^b [17]	Scheduled treatment interruptions^c	−1.2	−2.2%	0.19	0.4	0.8%	−0.15
Huang et al. 2008 [14]	TPV/r (tipranavir / ritonavir)	0.2	0.4%	−0.02	1.4	2.9%	−0.13
Huang et al. 2008 [14]	CPI/r (boosted comparitor PI)	−0.3	−0.6%	0.03	1.7	3.6%	−0.17
Powers et al. 2006 [18]	Intermittent group^d	0.6	1.1%	−0.07	3.2*	5.9%	−0.37
Powers et al. 2006 [18]	Continuous group^e	1.0	1.9%	−0.09	3.2	5.9%	0.00
Average for treatment-experienced patients [weighted]		−0.2	0.0	0.04	1.5	0.0	−0.13
Overall mean [weighted]		0.7	0.1	−0.19	1.8	0.1	−0.27

Mean change calculated as final score – baseline score. % change calculated as [(final score - baseline score) / baseline score] × 100. Effect size calculated as (final score – baseline score) / standard deviation of baseline score.
*P<0.05; Note: significance of mean change scores not available for all studies; ^aProspective non-randomized controlled trial; ^bPatient population includes treatment-naïve and treatment-experienced patients (analyzed together); ^cCD4-guided treatment with threshold of 350 cells/μL for interruption/re-initiation of ARV therapy; ^d7 cycles of 4 weeks off/8 weeks on HAART; ^eContinue HAART regimen for 22 weeks.

ISSN: 1477-7525